Date published: 2026-1-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

Gucy2g Activators

The chemical class known as Gucy2g Activators encompasses a specific group of compounds designed to enhance the activity of the Gucy2g enzyme. Gucy2g, also referred to as Guanylate Cyclase 2G, is an enzyme integral to various physiological processes, particularly in sensory systems like vision and olfaction. This enzyme functions by catalyzing the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), a crucial secondary messenger in cellular signaling. The role of Gucy2g is especially significant in signal transduction pathways, where the production of cGMP mediates various biological responses. Activators targeting Gucy2g are developed with the intention of promoting the enzyme's catalytic activity, thereby augmenting the generation of cGMP. This enhanced activity of Gucy2g can potentially influence the efficiency of signal transduction pathways in which cGMP plays a pivotal role, impacting the physiological functions reliant on these pathways.

The development of Gucy2g Activators is a complex and interdisciplinary endeavor, integrating insights from molecular biology, enzymology, and pharmacology. The initial phase of this process involves gaining a comprehensive understanding of the structure, function, and regulatory mechanisms of the Gucy2g enzyme. Techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational molecular modeling are employed to acquire detailed insights into the enzyme's active site and its interaction with substrates. This foundational knowledge is essential for the rational design of activators that can effectively interact with Gucy2g and induce its activation. Typically, these activators are small molecules or peptides, designed to efficiently bind to the enzyme and facilitate the catalytic conversion of GTP to cGMP. The molecular design of these activators is carefully optimized to ensure strong and specific interactions with Gucy2g, often targeting key domains or residues essential for the enzyme's activity. The efficacy of these activators is evaluated through various biochemical assays and cellular studies. These assays are crucial for assessing the activators' potency, specificity, and overall impact on Gucy2g-mediated pathways, providing key insights into their behavior and mechanism of action. Such research is fundamental for understanding the potential of Gucy2g Activators in modulating cellular signaling processes and their implications in physiological functions governed by cGMP signaling pathways.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Tadalafil

171596-29-5sc-208412
50 mg
$180.00
13
(2)

Tadalafil works similarly to sildenafil as a phosphodiesterase inhibitor, potentially influencing Gucy2g expression by altering cGMP levels.

Vardenafil

224785-90-4sc-362054
sc-362054A
sc-362054B
100 mg
1 g
50 g
$526.00
$735.00
$16653.00
7
(1)

Vardenafil is another phosphodiesterase inhibitor that may have indirect effects on Gucy2g expression through its impact on cGMP concentrations.

Zaprinast (M&B 22948)

37762-06-4sc-201206
sc-201206A
25 mg
100 mg
$105.00
$250.00
8
(2)

Zaprinast increases cGMP levels by inhibiting phosphodiesterase, which may influence Gucy2g expression in the retina.

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$77.00
$216.00
18
(1)

Rolipram is a phosphodiesterase inhibitor that primarily increases cAMP but could also have secondary effects on cGMP and related gene expression.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

IBMX non-selectively inhibits phosphodiesterases, potentially affecting cGMP levels and indirectly Gucy2g expression.

Cilostazol

73963-72-1sc-201182
sc-201182A
10 mg
50 mg
$109.00
$322.00
3
(1)

Cilostazol inhibits phosphodiesterase 3 and increases cAMP, with possible downstream effects on cGMP pathways and Gucy2g expression.

Theophylline

58-55-9sc-202835
sc-202835A
sc-202835B
5 g
25 g
100 g
$20.00
$32.00
$85.00
6
(0)

Theophylline is a non-selective phosphodiesterase inhibitor that could have indirect effects on cGMP levels and potentially Gucy2g expression.

Dipyridamole

58-32-2sc-200717
sc-200717A
1 g
5 g
$31.00
$102.00
1
(1)

Dipyridamole inhibits phosphodiesterase activity and may have an indirect role in regulating Gucy2g expression by influencing purinergic signaling.

Vinpocetine

42971-09-5sc-201204
sc-201204A
sc-201204B
20 mg
100 mg
15 g
$55.00
$214.00
$2400.00
4
(1)

Vinpocetine is a phosphodiesterase inhibitor that may indirectly affect Gucy2g expression through modulation of cGMP levels.

Pentoxifylline

6493-05-6sc-203184
1 g
$20.00
3
(1)

Pentoxifylline inhibits phosphodiesterase and may indirectly influence Gucy2g expression through changes in cyclic nucleotide levels.